JPRN-jRCT2031210069已完成1 期
A Phase 1 study to assess the safety, tolerability, and immunogenicity of VN-0200 after intramuscular injection in Japanese healthy adults and elderly subjects
Inoguchi Akihiro0 个研究点目标入组 48 人开始时间: 2021年5月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Japanese healthy subjects.
- •2. Age >=20 and <=50 years upon providing informed consent at step1 or Age >=65 and <=80 years upon providing informed consent at step2.
- •3. Body mass index (BMI) >=18.0 and <30.0 kg/m2 at screening.
排除标准
- •1. Subjects with a history of anaphylaxis or severe allergies due to food, medicine, insect bites, cosmetics, or vaccination
- •2. Having alcohol or drug dependence etc.
研究者
相似试验
已完成
1 期
Safety and pharmacokinetics study in healthy Japanese volunteersJPRN-jRCT2051210087Owada Yasuko48
已完成
不适用
A Phase I study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of HTX-011-19 (a long acting formulation of 5% bupivacaine and 0.15% meloxicam) and HTX-011-49 (a long acting formulation of 2.5% bupivacaine and 0.075% meloxicam) after subcutaneous administration in healthy subjects.post-operative painanalgesicsNL-OMON41936Heron Therapeutics, Inc.46
已完成
1 期
ART-001 Phase 1 studyHealthy volunteersJPRN-jRCT2080225277ARTham Therapeutics Inc.32
已完成
1 期
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of ART-648/TAK-648 in healthy Japanese volunteersHealthy volunteersJPRN-UMIN000034454Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine44
已完成
不适用
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of OMS1029 with single-dose intravenous and subcutaneous administration in healthy subjectsNL-OMON53550Omeros Corporation48